エムバイオテック


			Message from President
			Mycoplasma Infectious Diseases (MID) are systemic illnesses that cause vasculitis and neuritis. MID not only includes pneumonia but also diseases such as asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, and hematologic illnesses. The broader concept of MID encompasses acute to chronic phases with diverse symptoms. Therefore, it is often confusing and difficult to identify Mycoplasma-infected patients among those with incurable diseases, such as autoimmune diseases, rheumatic diseases, nervous system disorders, and hematological disorders. Because the appearance of drug-resistant mycoplasma, the early diagnosis and therapy of MID become more important. The problem of contamination to vaccine and biological products, and also transplantation and regenerative cell culture, it becomes critically important to establish medical system, in which to see mycoplasma infectious state and diagnose precisely. Regrettably, conventional diagnosis has only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. The cutting-edge technology has made it possible to measure the amount of specific antibodies to species-specific mycoplasma glycolipid-antigens. This new technology provides a reliable marker to follow the state of MID by monitoring antibody titer fluctuations. This advanced medicine can be applied to the differential diagnosis of side effects of drugs, including interstitial pneumonia and Stevens-Johnson syndrome. Furthermore, it is useful companion diagnostics, for the development of curative medicine, a vaccine, an antibody drug, an immune therapy. The vaccine for Mycoplasma Infectious Diseases (MID) is innovative human vaccine (First-in-class), which does not need adjuvant. The contribution from various medical fields will be beneficial to develop preventative health care to improve patient quality of life and reduce overall medical expenses. Furthermore, it is necessary to build medical networks for reconstitution of mycoplasma surveillance system from the national level to the global level, and to establish medical treatment guideline for MID. M Bio Technology Inc. is the research-and-development type venture business established on January 5, 2005. M Bio Technology Inc. is focusing the diagnosis, therapeutic and prevention with Mycoplasma Infectious Diseases. Mycoplasma infection cause not only pneumonia but asthma, arthritis, nephritis, meningitis, encephalitis, arteritis, dermatitis, etc., and presents variegated condition, such as autoimmune diseases, rheumatic disease and a nervous system disorders, innflammatory diseases. M Bio Technology Inc. is aiming for bussiness development on the mycoplasma lipid-antigen technologies.The diagnosis and drug design to the pathogenic microbe using the synthesized lipid antigen are world's first platform technology, and, would like to explore mutual business opportunities, in the field of diagnostics and vaccines. We would like to create an open innovation and global development are promoted, and wish joint development, a business tie-up, and the information and support relevant to a finance.

			Kazuhiro Matsuda, M.D.,Ph.D. Director of Mycoplasma Infectious Diseases Research Center (MIDRC), M Bio Technology Inc Education 1985 M.D. : Yamaguchi University School of Medicine 1990 Ph.D. : Yamaguchi University School of Medicine, International Medicine Professional Experience 1993-1998 Assistant Professor : Dept. of Microbiology of Tokyo Medical and Dental University 1997-1998 Special Volunteer : Laboratory of Biophysical Chemistry, National Heart, Lung and Blood Institute, National Institute of Health 1998-2005 Senior Scientist : National Cancer Center Reseach Institute 2005- CSO & Director : M Bio Technology Inc. 2005-2011 Visiting Scientist : National Institute of Advanced Industrial Science and Technology 2012- Director : Mycoplasma Infectious Diseases Research Center (MIDRC), M Bio Technology Inc.